Multiple Pluripotent Stem Cell Markers in Human Anaplastic Thyroid Cancer: The Putative Upstream Role of SOX2

Valeria Carina,¹ Giovanni Zito,¹ Giuseppe Pizzolanti,¹ Pierina Richiusa,¹ Angela Criscimanna,¹ Vito Rodolico,² Laura Tomasello,¹ Maria Pitrone,¹ Walter Arancio,¹ and Carla Giordano^{1,3}

Background: Anaplastic thyroid carcinoma (ATC) is a rare and aggressive endocrine tumor with highly undifferentiated morphology. It has been suggested that cancer stem cells (CSCs) might play a central role in ATC. The objectives of this study were (i) to characterize CSCs from *ex vivo* ATC specimens by investigating the expression of several pluripotent stem cell markers, and (ii) to evaluate *in vitro* drug resistance modifications after specific CSC transcription factor switch-off.

Methods: In *ex vivo* experiments, eight formalin-fixed, paraffin-embedded ATC specimens were analyzed by reverse-transcription and real-time quantitative PCR and immunohistochemistry. In *in vitro* experiments using ATC SW1736 cells, the expression levels of *OCT-4*, *NANOG*, and *ABCG2* and the sensitivity to either cisplatin or doxorubicin were evaluated after silencing.

Results: *OCT-4*, *KLF4*, and *SOX2* transcription factors and *C-KIT* and *THY-1* stem surface antigens showed variable up-regulation in all ATC cases. The SW1736 cell line was characterized by a high percentage of stem population ($10.4 \pm 2.1\%$ of cells were aldehyde dehydrogenase positive) and high expression of several CSC markers (*SOX2*, *OCT4*, *NANOG*, *C-MYC*, and *SSEA4*). *SOX2* silencing down-regulated *OCT-4*, *NANOG*, and *ABCG2*. *SOX2* silencing sensitized SW1736 cells, causing a significant cell death increase (1.8-fold) in comparison to control cells with $10 \mu\text{M}$ cisplatin ($93.9 \pm 3.4\%$ vs. $52.6 \pm 9.4\%$, $p < 0.01$) and 2.7 fold with $0.5 \mu\text{M}$ doxorubicin ($45.8 \pm 9.9\%$ vs. $17.1 \pm 3.4\%$ $p < 0.01$). *ABCG2* silencing caused increased cell death with both cisplatin ($74.9 \pm 1.4\%$) and doxorubicin treatment ($74.1 \pm 0.1\%$) vs. no-target-treated cells (respectively, $45.8 \pm 1.0\%$ and $48.6 \pm 1.0\%$, $p < 0.001$).

Conclusions: The characterization of CSCs in ATC through the analysis of multiple pluripotent stem cell markers might be useful in identifying cells with a stem-like phenotype capable of resisting conventional chemotherapy. In addition, our data demonstrate that *SOX2* switch-off through *ABCG2* transporter down-regulation has a major role in overcoming CSC chemotherapy resistance.

Introduction

ANAPLASTIC THYROID CARCINOMA (ATC) is a rare, aggressive, and lethal endocrine cancer with morphological features of an undifferentiated neoplasm. Around 50% of patients have metastases at presentation, while another 25% develop new metastases soon after diagnosis. Due to the rapid fatal course, surgery is rarely performed and generally only for compressive symptoms. Radiotherapy and chemotherapy are not fully effective, perhaps because they do not adequately target the cancer-initiating cells (1).

Adult stem cells have been identified in normal human thyroid glands (2). A link between stem and cancer cells has been claimed for tumors supposedly deriving from immature

progenitors/stem cells or from formerly normal cells that have acquired stem-like properties (3). So far, cancer stem cells (CSCs) have been isolated based on the expression of specific surface molecules (4–8), which have been associated with aggressive and metastatic behavior and not with “stemness” *per se*. Regarding ATC, it has been hypothesized that the tumor initiates from the remnants of fetal thyroid cells, rather than from adult thyrocytes undergoing a multi-step carcinogenesis model (9). Unfortunately, the relative rarity and rapidly fatal nature of ATC has limited functional studies on *ex vivo* tissues. Here we describe the expression of a panel of CSC markers in ATC specimens and in ATC cell line SW1736, a well-validated ATC cell line (10), by analyzing surface and nuclear transcription factors, the latter implicated

¹Laboratory of Molecular Endocrinology, Section of Endocrinology, Biomedical Department of Internal and Specialized Medicine (Di.Bi.M.I.S.); ²Institute of Pathological Anatomy; University of Palermo, Palermo, Italy.

³A. Monroy Institute of Biomedicine and Molecular Immunology (CNR-IBIM), Palermo, Italy.

in self-renewal and maintenance of CSC pluripotency, as well as aldehyde dehydrogenase activity (ALDH) (11). Moreover, the role of these markers in drug sensitivity was assessed in the SW1736 cell line.

Methods

Specimens

This study was approved by the Institutional Review Board at the Faculty of Medicine of the University of Palermo. At the time of surgery, all patients signed an informed consent for the scientific use of their data (12).

Eight archival formalin-fixed, paraffin-embedded ATC tissue specimens were used for this study. Diagnosis of ATC was performed by two independent pathologists according to the current classification (13). Normal thyroid tissues from 12 cases contralateral to the lobe with papillary thyroid tumor (less than 1 cm) were used as control samples.

Immunohistochemistry

Five-micrometer sections were analyzed for the expression of SSEA4 and SOX2. Briefly, for SSEA4, tissue sections were deparaffinized, rehydrated, and microwave-heated in 10 mM sodium citrate buffer for antigen retrieval. Sections were then incubated with 3% hydrogen peroxide in phosphate-buffered saline (PBS) for 5 minutes, and blocked with 3% bovine serum albumin (BSA) in PBS. Incubation with mouse anti-human SSEA4 (IgG3, clone 813-70, Santa Cruz Biotechnology, Santa Cruz, CA) was performed at room temperature for 1 hour. Expression was detected with secondary biotinylated antibodies, streptavidin/horseradish peroxidase and chromogen 3-amino-9-ethylcarbazole substrate. For SOX2, the semi-automated Ventana system was used according to the manufacturer's instructions (BenchMark XT, Ventana Medical Systems, Inc., Tucson, AZ), antigens were unmasked in CC1 (Ventana Medical Systems, Inc.) for 90 minutes, and sections were incubated with rabbit antihuman SOX2 (Poly6308, BioLegend, San Diego, CA) at 37°C for 1 hour. Expression was detected with the DAB ultraView Universal detection kit (Ventana Medical Systems, Inc.). Slides were counterstained with hematoxylin and eosin and blueing reagent according to the manufacturer's instructions. The number of SSEA4⁺ and SOX2⁺ cells was assessed in light microscopy. For each case, a minimum of 10³ cells was counted in three randomly collected sections, and the percentage of positive cells was regarded as the labeling index (LI).

Reverse-transcription PCR and real-time quantitative PCR

Total RNA was extracted from 10 μ m sections using High Pure RNA Paraffin Kit (Roche Diagnostics GmbH, Mannheim, Germany) or from cultured SW1736 cells using the RNeasy Mini Kit (Qiagen, Milan, Italy), including a digestion step with DNase I. RNA quantity and quality were assessed by UV spectrophotometry. The RNA extracted was reverse-transcribed with Random Hexamers (Applied Biosystems, Darmstadt, Germany) and Improm II Reverse Transcriptase (Promega Italia, Milan, Italy), according to the manufacturer's protocol. Thyroglobulin (TG), thyroperoxidase (TPO), sodium/iodide symporter (NIS), and oncofetal fibronectin (onfFN) were analyzed with reverse-

transcription (RT)-PCR as previously described (14). Briefly, primer pair sequences, cDNA fragment sizes and annealing temperatures were as follows: TG (762 bp), 5'-CTT CGA GTA CCA GGT TGA TGC C-3' and 5'-GGT GGT TTC AGT GAA GGT GGA A-3' (55°C); TPO (593 bp), 5'-TGT GTC CAA CGT GTT CTC CAC AG-3' and 5'-AAG ACG TGG CTG TTC TCC CAC-3' (55°C); NIS (179 bp), 5'-CTA TGG CCT CAA GTT CCT CT-3' and 5'-TCG TGG CTA CAA TGT ACT GC-3' (57°C); and onfFN (215 bp), 5'-TCT TCA TGG ACC AGA GAT CT-3' and 5'-TAT GGT CTT GGC TAT GCC T-3' (55°C). *KLF4*, *SOX2*, *OCT-4*, *C-MYC*, *C-KIT*, *THY-1*, *PAX-8*, *ABCG2*, and *TTF-1* expression was analyzed by real-time quantitative PCR (qRT-PCR) using Quantitect SYBR Green PCR kit (Qiagen, Milan, Italy). PCR primers and probes were also purchased from Qiagen. All reactions were performed using a LightCycler 1.5 Instrument (Roche Diagnostics GmbH). Gene expression was normalized against the housekeeping gene β -actin, which was stable among all the samples (For: 5'-GGA CTT CGA GCA AGA GAT GG-3', and Rev: 5'-AGC ACT GTG TTG GCG TAC AG-3').

Cell cultures

The SW1736 cell line was cultured in Dulbecco's modified Eagle's medium high glucose medium supplemented with 10% fetal bovine serum and 5% glutamine. Cultures were maintained in 5% carbon dioxide at 37°C in a humidified incubator.

Immunocytochemistry

SW1736 cells were plated in chamber slides (Lab-Tek, Nunc, Inc., Naperville, IL), allowed to attach for 24 hours and then used for immunocytochemistry. Cells were fixed in 2% paraformaldehyde in PBS for 20 minutes at room temperature, then washed twice in PBS, blocked with 5% BSA and permeabilized for 10 minutes at room temperature with a blocking solution containing 0.1% saponin. Cells were incubated with rabbit anti-human SOX2 (Poly6308, BioLegend, San Diego, CA) and/or mouse anti-human SSEA4 (IgG3, clone 813-70, Santa Cruz Biotechnology) in blocking solution containing saponin overnight at 4°C and subsequently rinsed again with blocking solution plus saponin. The secondary antibodies used were AF594 goat anti-rabbit IgG, AF488 goat anti-mouse IgG3 (Invitrogen, Carlsbad, CA). Cells were counterstained with 4',6-diamidino-2-phenylindole (DAPI) 0.5 μ g/mL (Sigma-Aldrich, St. Louis, MO).

Flow cytometry

The identification of ALDH⁺ cells was performed using the ALDEFLUOR kit (StemCell Technologies, Voden Milan, Italy). In accordance with manufacturing procedures, as a negative control, an aliquot of cells from each sample was treated with 50 mmol/L of diethylaminobenzaldehyde, a specific ALDH inhibitor, and intracellular fluorescent product was measured by flow cytometry (FACSCalibur, Becton Dickinson, San Jose, CA).

Confocal and two-photon microscopy

Fluorescence images were acquired in 1024 $\times$ 1024 format in three channels by means of a Leica TCS SP5 inverted Laser Scanning Confocal Microscope using an HCX PL APO CS 63.0 $\times$ 1 oil objective NA=1.4 (Leica Microsystems, Leica, Wetzlar, Germany); the pinhole size was 80 μ m. Images were sequentially acquired using a scanning frequency of 400 Hz.

Alexa 488 dye was excited using the 488 nm line of an Argon laser and fluorescence signal was acquired in the range 500–550 nm (green channel). DAPI and Alexa 594 dye were excited using a pulsed infrared laser source: “Mai Tai” (Spectra-Physics Santa Clara, CA) tuned at 760 nm with two-photon excitation. The emission spectral ranges were set to 390–460 nm for DAPI (blue channel) and 600–670 nm for Alexa 594 (red channel).

siRNA transfection

siRNAs transfection in SW1736 cells was performed using INTERFERinTM transfection agent (Polyplus-Transfection, Illkirch, France), according to the manufacturer's instructions. Briefly, cells were seeded into six-well plates at a density of 250,000 cells/well or 96-well plates at a density of 3000 cells/well. The transfection agent and the siRNA complex were added to the cells and incubated for 72 hours for mRNA analysis and 96 hours for protein detection. The final concentration of SOX2 siRNA was 100 nM for mRNA analysis and 150 nM for protein detection and 40 nM for OCT-4 and ABCG2 siRNA. Each assay was performed in triplicate in at least three independent experiments. SOX2 was silenced using Stealth siRNA SOX2 HSS144045 (Invitrogen, Milan, Italy). siCONTROL Stealth siRNA Negative Control was used as a control (Invitrogen, Milan). OCT-4 and ABCG2 were silenced by Oct-3/4 and ABCG2 siRNA (h) (Santa Cruz Biotechnology), and control siRNAs were used as a no-target control (Santa Cruz Biotechnology).

Cytotoxicity

SW1736 cells were plated in 96-well plates in a 100 μ L medium/well containing 100 nM of SOX2 siRNA or ABCG2 siRNA (h) or siCONTROL or 0.5 μ L of INTERFERinTM alone. After 24 hours the medium was refreshed and the cells were cultured with 0.5, 1.5, or 10 μ M cisplatin (Pharma, Leobendorf Kundl, Austria) or 0.5, 1, or 1.5 μ M doxorubicin (Ebewe Pharma, Leobendorf Kundl, Austria) up to 48 hours. Cell proliferation was assessed by a colorimetric assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich). Absorbance was read at 550 nm in a MultiskanFC microplate reader (Thermo Fisher Scientific, Milan, Italy).

Protein extraction and Western blot analysis

Proteins were extracted from cultured cells using Radio-ImmunoPrecipitation Assay (RIPA) buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Nonidet P40), supplemented with a protease inhibitor cocktail (Complete mini, Roche Diagnostics GmbH) and phosphatase inhibitors. Protein content was determined according to Bradford's method. Proteins were separated by NuPAGE[®] 4–12% Bis-Tris Gel (Invitrogen, Milan), electrotransferred to nitrocellulose membrane, and blotted with the following primary antibodies: rabbit antihuman SOX2 (Poly6308, BioLegend, San Diego, CA), mouse antihuman Oct-4 (sc-5279, Santa Cruz Biotechnology), goat antihuman Nanog (sc-30331, Santa Cruz Biotechnology), mouse antihuman ABCG2 (sc-58222 Santa Cruz Biotechnology), rabbit antihuman Akt1/2/3 (sc-8312 Santa Cruz Biotechnology), rabbit antihuman p-Akt1/2/3 (sc-293095 Santa Cruz Biotechnology), and mouse anti β -actin IgG1 (A5441, Sigma-Aldrich). Secondary antibodies were goat anti-rabbit IgG-HRP (sc-2030, Santa Cruz Biotechnology), goat anti-mouse IgG-HRP (sc-2031, Santa Cruz Biotechnology), and donkey anti-goat IgG-HRP (sc-2033, Santa Cruz Biotechnology). Antigen-antibody complexes were visualized using the SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific) on a CCD camera (Chemidoc, Bio-Rad, Milan, Italy). Western blot bands were quantified with ImageJ software (National Institutes of Health, Bethesda, MD).

Statistical analysis

Statistical analysis (*t*-test, two-tailed, with confidence interval at 95%) was performed with GraphPad Prism 5 software for Windows (GraphPad Software, Inc., La Jolla, CA).

Results

ATC is a highly undifferentiated tumor

RT and qRT-PCR analysis were performed for mature and fetal thyrocyte markers. Expression of *TG*, *TPO*, and *NIS* was never detected, indicating the undifferentiated status of ATC specimens. By contrast, *onfFN*, *PAX-8*, and *TTF-1* were positive in all eight cases, proving the thyroidal origin of the tumors (Fig. 1A–C).

FIG. 1. RT-PCR (A) and qRT-PCR (B, C) analysis for mature and fetal thyrocyte markers. Absence of *TG*, *TPO*, and *NIS* confirms the undifferentiated status of ATC specimens (A: lanes 1–8, ATC; lane 9, normal thyroid; 10, negative control). Expression of *onfFN*, *PAX-8*, and *TTF-1* proves the thyroidal origin of the tumors (B, C). Values are shown as mean $\pm$ SE. ATC, anaplastic thyroid carcinoma; bp, base pairs; RT-PCR, reverse-transcription PCR; qRT-PCR, real-time quantitative PCR; TG, thyroglobulin; TPO, thyroperoxidase; NIS, sodium/iodide symporter.

FIG. 2. Expression of pluripotent stem cell nuclear transcription factors and surface stem cell markers in ATC. qRT-PCR analysis of nuclear stem cell transcription factors (A–D) and surface stem cell markers (E–F). Values were normalized to normal thyroid (see *Methods*) and shown as mean $\pm$ SE. Data are representative of three independent experiments.

Identification of cancer and pluripotent stem cell markers in ATCs

All cases showed very variable hyperexpression of various stem cell markers in comparison with normal thyroid cells (see *Methods*) used for normalization. Nuclear (SOX2, OCT4, KLF4, and C-MYC) and surface (THY-1 and C-KIT) stem markers were evaluated by qRT-PCR (Fig. 2A–F) and *SSEA4* by immunohistochemistry (LI comprised between $35.8 \pm 3.3\%$ and $5.5 \pm 1.1\%$; Fig. 3B).

SW1736 characterization and “stemness”

The undifferentiated status of ATC cell line SW1736 was confirmed by PCR by the presence of *onfFN* and the absence of the thyrocyte-specific differentiating markers *TG*, *TPO*, and *NIS* (Fig. 4A). The constitutive activation of p-AKT was shown by Western blot analysis (Fig. 4B). The existence of stem cell population in this cell line was demonstrated by the higher expression of nuclear stem markers SOX2, OCT-4, NANOG, and C-MYC in SW1736 in comparison with normal

FIG. 3. Co-localization of SOX2 and SSEA4. (A) Confocal analysis: surface stem cell marker SSEA4 (green) and nuclear stem cell marker SOX2 (red) co-localized. Counterstaining was performed with 4',6-diamidino-2-phenylindole (DAPI, blue). For image acquisition and magnification see methods. (B) Immunohistochemistry: SSEA4 and SOX2 were strongly positive in the same four cases (20 $\times$ magnification).

FIG. 4. (A) SW1736 cell line characterization. RT-PCR analysis of thyrocyte markers in SW1736 cells. Lane 1, normal thyroid; lane 2, SW1736 cell line; lane 3, negative control; bp, base pairs. (B) Western blot analysis of AKT and p-AKT. (C) qRT-PCR analysis of relative expression of *SOX2*, *OCT-4*, *NANOG*, and *C-MYC* in the SW1736 cell line (□) vs. normal thyroid (■). Data are representative of three independent experiments. Values are shown as mean $\pm$ SE. ** $p < 0.001$, *** $p < 0.0001$. (D) FACS analysis of SW1736 cells using ALDEFLUOR assay. Thyroid cancer cells exposed to ALDEFLUOR substrate and a specific inhibitor of aldehyde dehydrogenase (ALDH) (i) were used to define the population with high ALDH activity (ii). SSC-H, side light scatter; FL1-H, fluorescence channel.

thyroid cells (Fig. 4C) and by the identification of a high percentage ($10.4 \pm 2.1\%$) of ALDH⁺ cells (Fig. 4D). Interestingly, our confocal analysis showed co-localization of the stem cell markers SSEA4 and SOX2 (Fig. 3A). Our *in vitro* findings are in agreement with what we found in human tumor specimens, in which 50% of the tumors analyzed (ATC1, 2, 3, 4) overexpressed both SSEA4 and SOX2 (Fig. 3B).

SOX2 expression and silencing in SW1736 cell line

In SW1736 cell lines, *SOX2* was more highly expressed compared with both *OCT-4* and the downstream gene *NANOG* (Fig. 5A). Thus, to establish the relationship between *SOX2*, *OCT-4*, *NANOG*, and *ABCG2*, we evaluated their expression after *SOX2* silencing. As expected, *SOX2* silencing (1.76 ± 0.03 vs. 0.60 ± 0.01 , $p < 0.0001$, optical density [OD] 42.45 vs. 18.62) caused down-regulation of the downstream genes *NANOG* (0.55 ± 0.07 vs. 0.07 ± 0.02 , $p < 0.01$; OD 24.5 vs. 4.2) and *ABCG2* (4.99 ± 0.03 vs. 1.09 ± 0.17 , $p < 0.0001$, OD 39.8 vs. 13.8), but also caused a decrease in *OCT-4* expression (2.55 ± 0.19 vs. 0.83 ± 0.03 , $p < 0.001$, OD 26.2 vs. 1.3) (Fig. 5B–G). By contrast, *OCT-4* silencing (0.87 ± 0.02 vs. 0.38 ± 0.05 , $p < 0.0001$) showed no effect on *SOX2* expression (Fig. 5H, I).

SOX2 switch-off effect on cisplatin and doxorubicin treatment

SOX2 is involved in mediating regulation on SW1736 resistance to cisplatin (median inhibition concentration [IC₅₀]

$10.9 \pm 2.5 \mu\text{M}$ at 48 hours) and doxorubicin (IC₅₀ $4.9 \pm 2.0 \mu\text{M}$ at 48 hours) in SW1736 cells. The MTT assay showed that *SOX2* silencing caused chemosensitization in siRNA-treated cells compared to no-target-treated cells. Treatment with 1.5 or $10 \mu\text{M}$ cisplatin caused $59.3 \pm 1.2\%$ and $93.9 \pm 3.4\%$ of cell death, respectively, in *SOX2* siRNA-treated cells vs. $44.9 \pm 2.3\%$ ($p < 0.001$) and $52.6 \pm 9.4\%$ ($p < 0.01$) in no-target-treated cells. Doxorubicin treatment at 0.5 or $1 \mu\text{M}$ caused $45.8 \pm 9.9\%$ and $51.2 \pm 2.5\%$ of cell death in silenced cells vs. $17.1 \pm 3.4\%$ ($p < 0.01$) and $35.7 \pm 9.9\%$ ($p < 0.05$) in unsilenced cells (Fig. 6A).

ABCG2 switch-off effect on cisplatin and doxorubicin treatment

To investigate the mechanism whereby *SOX2* silencing causes cisplatin and doxorubicin chemosensitization, we analyzed the effect of the drug on *ABCG2*. The silencing of *ABCG2* ($66.2 \pm 3.1\%$, $p < 0.001$, data not shown) was associated with a sensitization to cisplatin and doxorubicin. The MTT assay showed that treatment with 0.5, 1.5, or $10 \mu\text{M}$ cisplatin, respectively, caused $59.2 \pm 1.1\%$, $61.2 \pm 0.6\%$, and $74.9 \pm 1.4\%$ of cell death in *ABCG2* siRNA-treated cells vs. $28.5 \pm 4.0\%$, $44.8 \pm 1.6\%$, and $45.8 \pm 1.0\%$ ($p < 0.001$) in no-target-treated cells. Doxorubicin treatment at 0.5, 1.0, and $1.5 \mu\text{M}$, respectively, caused $15.9 \pm 1.4\%$, $44.0 \pm 0.3\%$, and $74.1 \pm 0.1\%$ of cell death in silenced cells vs. $4.2 \pm 0.1\%$, $24.4 \pm 2.6\%$, and $48.6 \pm 1.0\%$ in unsilenced cells ($p < 0.001$; Fig. 6B).

FIG. 5. Analysis of SOX2 silencing. qRT-PCR analysis in the SW1736 cell line (**A**); SOX2 (**B**), NANOG (**C**), ABCG2 (**D**), and OCT-4 (**E**) expression in the SW1736 cell line after SOX2 silencing with stealth siRNA (siSOX2) vs. siCONTROL treated cells (Control). Western blot (**F**, **G**) of SOX2, OCT-4, and NANOG with proteins extracted from SW1736 cells after SOX2 silencing with stealth siRNA (□) vs. siCONTROL treated cells (■). Analysis of OCT4 silencing: OCT4 (**H**) and SOX2 (**I**) expression in the SW1736 cell line after OCT-4 silencing with siRNA (siOCT-4) vs. siCONTROL treated cells (Control). Data are representative of three independent experiments. Values are shown as mean $\pm$ SE. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. OD, optical density.

Discussion

The existence of CSCs may account for the high degree of dedifferentiation, sustained proliferation, and resistance to chemotherapy of ATC lesions (9,14). It has been demonstrated that murine and human somatic cells can be induced into pluripotent stem cells with a combination of four defined transcription factors (OCT-4/NANOG plus either C-MYC/KLF4 or SOX2/LIN28) (14,15). Indeed, these transcription factors play a pivotal role in the maintenance of pluripotency and self-renewal of embryonic stem cells and could therefore be responsible for sustained growth of ATC. Interestingly, in all eight specimens obtained from the archives of the Pathology Department at the University of Palermo, we found variable expression of stem nuclear transcription markers SOX2, OCT-4, C-MYC, and KLF4. In addition, all ATCs also

showed up-regulation of the stem cell-related surface markers C-KIT and THY-1, which have also been described in several other tumors (16–19) and SSEA4 expression, a human embryonic surface stem cell marker, which has been proposed for the identification of CSCs in undifferentiated tumors (20). Though the low number of ATC tissues used cannot provide a definitive result, the findings of this study may indicate that cells with a pluripotent phenotype exist within the tumor, consistent with the CSC hypothesis, but with very marked variability in stem marker expression, suggesting the need for a panel of markers and the invalidity of a single marker. In our ATC cases, indeed, CD133 was only overexpressed in four cases and LIN28 and NANOG were never detected, while in the SW1736 cell line, NANOG was strongly expressed and C-KIT, THY-1, CD133, LIN28, and KLF4 were not detected (data not shown). It is noteworthy that SOX2 and SSEA4 were

FIG. 6. Effects of *SOX2* and *ABCG2* silencing on chemosensitivity. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) analysis after cisplatin (i) and doxorubicin (ii) treatment of SW1736 cells after *SOX2* (A) or *ABCG2* (B) silencing with stealth siRNA (siRNA, ●) vs. siCONTROL treated cells (Control, ■). Data are representative of three independent experiments. Values are shown as mean $\pm$ SE. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

simultaneously overexpressed in the same *ex vivo* ATC cases (ATC1, 2, 3, 4) and were found to be co-localized in the SW1736 cell line.

Recent studies have shown a central role of *SOX2* in stem cell behavior (21,22). In particular, in malignant glioblastoma, *SOX2* proved to be amplified or overexpressed, and ectopic *SOX2* expression was not only sufficient to induce invasion and migration of glioma cells, but was also essential for maintaining these properties (21). This gene has been described as being involved in sustaining self-renewal of several stem cells, in particular neural stem cells (22). Moreover, silencing of *SOX2* in freshly derived glioblastoma tumor-initiating cells stopped proliferation and caused lack of tumorigenicity in immunodeficient mice. Consequently, *SOX2* or its immediate downstream effectors have been considered an ideal target for glioblastoma therapy (22). Recent studies have shown that *SOX2* overexpression occurs in several other human malignant tumors; for example, in 43% of basal cell-like breast carcinomas and 41% of small cell lung cancers (23,24). The relationship between aberrant expression of *SOX2*, *OCT-4*, and *NANOG* in cancer has been studied in various cancers (25–27). Moreover Masui *et al.* (25) showed that *SOX2* is indispensable for maintaining embryonic stem cell pluripotency. Thus, in embryonic stem cells the expression of most pluripotency-associated genes, including *NANOG*, is regulated by an enhancer containing *OCT-4* and *SOX2* binding motifs (28). In this study we showed that *SOX2* was overexpressed not only in ATC specimens in comparison with normal thyroid, but also in the SW1736 cell line, where it plays a pivotal role. Indeed, in this model *SOX2* was expressed more abundantly than both stem nuclear transcription factors *OCT-4* and *NANOG*. Moreover, *SOX2* silencing by RNA interference (siRNA) caused down-regulation not only of the downstream *NANOG* gene but also of *OCT-4*, confirming that *SOX2* is able to regulate *OCT-4* (27,29). In addition, *SOX2* down-regulation caused chemosensitization to cisplatin and doxorubicin. Our findings suggest that this chemosensitization could depend on down-regulation of

ABCG2, which was strongly down-regulated after *SOX2* silencing. Indeed, both chemotherapeutic agents are *ABCG2* substrates (30,31), and Zheng and co-workers (32) showed that *ABCG2* has a major responsibility for side population (stem cell-like subpopulation) resistance to doxorubicin in ATC treatment. Hence, our data strongly support a hierarchical model in which *SOX2* plays a central role. In this connection, *SOX2* is able to down-regulate *OCT-4*, but not vice versa. Moreover, several recent studies have shown that an important relationship exists between AKT pathway activation and *SOX2*, *OCT-4*, *NANOG*, and self-renewal capacity (33,34). In our study, SW1736 showed a constitutive expression of p-AKT, confirming the relationship between AKT and the self-renewal-related markers *SOX2* and *OCT-4*.

So far, we have confirmed the existence of CSCs in ATC tissues (9,14), showing that several stem cell markers are expressed in ATC specimens and in the SW1736 cell line, suggesting that a single marker cannot exclusively identify CSCs, and a pool of candidate antigens must be considered. Notably, both pluripotent nuclear transcription factors and surface antigens were mainly up-regulated in the same ATC cases and in SW1736 cell lines in which an *ALDH*⁺ population was also found. Analogous to other markers, *ALDH* activity is not a stem marker associated with a negative prognosis in all cancer types. Indeed, in malignant melanoma it seems not to correlate with “stemness” (35), and its role has also been challenged in ovarian cancer (36–38). On the other hand, an *ALDH1* activity increase has been associated with undifferentiated cells in numerous tissues, such as ovarian, breast, pancreatic, multiple myeloma, acute myeloid leukemia, and lung (37–43), and particularly in the human ATC-8505C cell line (44).

Taken together, these data further support the necessity of a panel of markers for identifying CSCs. In particular, *SOX2* appears to play a pivotal role in the resistance of ATC to chemotherapy by regulating *ABCG2* transporter gene expression, which is responsible for the efflux of drugs. In conclusion, the present work supports a hierarchical model

controlled by SOX2 in ATC and opens the way to finding new therapeutic strategies based on switching off SOX2 in order to further understand the potential involvement of CSCs in ATC.

Acknowledgments

We thank Valeria Militello and Valeria Vetri (Molecular Biophysics and Soft Matter Research Group, Department of Physics, University of Palermo, Palermo, Italy) for excellent technical assistance with fluorescence and confocal microscopy.

Disclosure Statement

The authors declare that no competing interests exist.

References

- Gharib H, Papini E, Paschke R 2008 Thyroid nodules: a review of current guidelines, practices, and prospects. *Eur J Endocrinol* **159**:493–505.
- Thomas T, Nowka K, Lan L, Derwahl M 2006 Expression of endoderm stem cell markers: evidence for the presence of adult stem cells in human thyroid. *Thyroid* **16**:537–544.
- Thomas D, Friedman S, Lin RY 2008 Thyroid stem cells: lessons from normal development and thyroid cancer. *Endocr Relat Cancer* **15**:51–58.
- Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, Jones RJ 2004 Characterization of clonogenic multiple myeloma cells. *Blood* **103**:2332–6.
- Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF 2003 Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci U S A* **100**:3983–3988.
- Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB 2003 Identification of a cancer stem cell in human brain tumours. *Cancer Res* **63**:5821–5828.
- O'Brien CA, Pollett A, Gallinger S, Dick JE 2006 A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. *Nature* **445**:106–110.
- Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, Gritti A, Piccinini A, Porro D, Santinami M, Invernici G, Parati E, Alessandri G, La Porta CA 2007 Melanoma contains CD133 and ABCG2 positive cells with enhanced tumorigenic potential. *Eur J Cancer* **43**: 935–46.
- Takano T, Amino N 2005 Fetal cell carcinogenesis: a new hypothesis for better understanding of thyroid carcinoma. *Thyroid* **15**:432–438.
- Schweppe RE, Klopfer JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR 2008 Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. *J Clin Endocrinol Metab* **93**:4331–4341.
- Alison MR, Lin WR, Lim SM, Nicholson LJ 2012 Cancer stem cells: in the line of fire. *Cancer Treat Rev* **38**:589–598.
- Pellegriti G, De Vathaire F, Scollo C, Attard M, Giordano C, Arena S, Dardanoni G, Frasca F, Malandrino P, Vermiglio F, Previtera DM, D'Azzò G, Trimarchi F, Vigneri R 2009 Papillary thyroid cancer incidence in the volcanic area of Sicily. *J Natl Cancer Inst* **101**:1575–1583.
- World Health Organization 2004 Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. First edition. IARC Press, Lyon.
- Zito G, Richiusa P, Bommarito A, Carissimi E, Russo L, Coppola A, Zerilli M, Rodolico V, Criscimanna A, Amato M, Pizzolanti G, Galluzzo A, Giordano C 2008 In vitro identification and characterization of CD133pos cancer stem-like cell in anaplastic carcinoma cell lines. *PLoS One* **3**(10):e3544.
- Reya T, Morrison SJ, Clarke MF, Weissman IL 2001 Stem cells, cancer, and cancer stem cells. *Nature* **414**:105–111.
- Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S 2007 Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* **131**:861–872.
- Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA 2007 Induced pluripotent stem cell lines derived from human somatic cells. *Science* **318**:1917–1920.
- Patnaik MM, Tefferi A, Pardanani A 2007 Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders. *Curr Cancer Drug Targets* **7**:492–503.
- Rege TA, Hagood JS 2006 Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. *FASEB J* **20**:1045–1054.
- Tokuyama S, Saito S, Takahashi T, Ohyama C, Ito A, Kanto S, Satoh M, Hoshi S, Endoh M, Arai Y 2003 Immunostaining of stage-specific embryonic antigen-4 in intratubular germ cell neoplasia unclassified and in testicular germ-cell tumours. *Oncol Rep* **10**:1097–1104.
- Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N, Urquiza L, Jauregi P, de Munain AL, Sampron N, Aramburu A, Tejada-Solis S, Vicente C, Otero MD, Bandrés E, García-Foncillas J, Idoate MA, Lang FF, Fueyo J, Gomez-Manzano C 2011 Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. *PLoS One* **6**:e26740.
- Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, Ravetti GL, Zona GL, Daga A, Corte G 2009 SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. *Stem Cells* **27**:40–48.
- Güre AO, Stockert E, Scanlan MJ, Keresztes RS, Jäger D, Altorki NK, Old LJ, Chen YT 2000 Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. *Proc Natl Acad Sci U S A* **97**:4188–4203.
- Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, Rodriguez-Gil Y, Martinez MA, Hernandez L, Hardisson D, Reis-Filho JS, Palacios J 2007 Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. *Mod Pathol* **20**:474–481.
- Masui S, Nakatake Y, Toyooka Y, Shimosato D, Yagi R, Takahashi K, Okochi H, Okuda A, Matoba R, Sharov AA, Ko MS, Niwa H 2007 Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. *Nat Cell Biol.* **9**:625–635.
- Gu GY, Yuan JL, Wills M, Kasper S 2007 Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. *Cancer Res* **67**:4807–4815.
- Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, Chou SH, Chien CS, Ku HH, Lo JF 2008 Positive correlations of Oct4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. *Clin Cancer Res* **14**: 4085–4095.

28. Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, Ng HH, Robson P 2005 Transcriptional regulation of nanog by OCT4 and SOX2. *J Biol Chem* **280**:24731–24737.
29. Xiang R, Liao D, Cheng T, Zhou H, Shi Q, Chuang TS, Markowitz D, Reissfeld RA, Luo Y 2011 Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. *Br J Cancer* **104**:1931.
30. Ceckova M, Vackova Z, Radilova H, Libra A, Buncek M, Staud F 2008 Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. *Toxicol In Vitro* **22**:1846–1852.
31. Calcagno AM, Fostel JM, To KK, Salcido CD, Martin SE, Chewning KJ, Wu CP, Varticovski L, Bates SE, Caplen NJ, Ambudkar SV 2008 Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. *Br J Cancer* **98**:1515–1524.
32. Zheng X, Cui D, Xu S, Brabant G, Derwahl M 2010 Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: characterization of resistant cells. *Int J Oncol* **37**:307–315.
33. Singh S, Trevino JG, Bora-Singhal N, Coppola D, Haura E, Altiock S, Chellappan SP 2012 EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. *Mol Cancer* **11**:73.
34. Lin F, Lin P, Zhao D, Chen Y, Xiao L, Qin W, Li D, Chen H, Zhao B, Zou H, Zheng X, Yu X 2012 Sox2 targets cyclinE, p27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis. *Cell Prolif* **45**:207–216.
35. Prasmickaite L, Engesaeter BØ, Skrbo N, Hellenes T, Kristian A, Nina K, Oliver NK, Suo Z, Mælandsmo GM 2010 Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. *PLoS One* **5**:e10731.
36. Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, Jinsong Liu J 2009 ALDH1 expression correlates with favorable prognosis in ovarian cancers. *Mod Pathol* **22**:817–823.
37. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Wicha MS, Buckanovich RJ 2011 Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. *Cancer Res* **71**:3991–4001.
38. Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, Banerjee M, Mao Y, Kotarski J, Wicha MS, Liu R, Zou W 2012 Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. *Int J Cancer* **130**:29–39.
39. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G 2007 ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. *Cell Stem Cell* **1**:555–567.
40. Jelski W, Chrostek L, Szmitkowski M 2007 The activity of class I, II, III, IV of alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in pancreatic cancer. *Pancreas* **35**:142–146.
41. Pearce DJ, Taussig D, Simpson C, Allen K, Rohatiner AZ, Lister TA, Bonnet D 2005 Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. *Stem Cells* **23**:752–760.
42. Ucar D, Cogle CR, Zucali JR, Ostmark B, Scott EW, Zori R, Gray BA, Moreb JS 2009 Aldehyde dehydrogenase activity as a functional marker for lung cancer. *Chem Biol Interact* **178**:48–55.
43. Taubert I, Saffrich R, Zepeda-Moreno A, Hellwig I, Eckstein V, Bruckner T, Ho AD, Wuchter P 2011 Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor. *Cytotherapy* **13**:459–466.
44. Klonisch T, Hoang-Vu C, Hombach-Klonisch S 2009 Thyroid stem cell and cancer. *Thyroid* **19**:1303–1315.

Address correspondence to:

Carla Giordano, MD
 Professor of Endocrinology
 University of Palermo
 Piazza delle Cliniche 2
 90127 Palermo
 Italy

E-mail: carla.giordano@unipa.it